Changi General Hospital

Geraldine Lim

Patient Safety Advocate

As deputy head at Changi General Hospital (CGH)'s Research Office, I have had the privilege of witnessing a vibrant ecosystem of innovation, collaboration and the evolution of clinical research. Reflecting on my career, several key experiences and milestones have profoundly shaped my leadership philosophy and approach to advancing clinical research.

Early in my career, I was involved in clinical trials that underscored the importance of meticulous data management and patient-centric approaches. A particularly memorable research project was a study that sought to enhance outcomes for patients with primary aldosteronism – a lesser-known, but curable form of hypertension. In collaboration with the CGH multidisciplinary care team, my team and I explored new blood tests to accurately measure aldosterone and renin hormones to better identify and diagnose patients with primary aldosteronism. Leveraging technology to enhance care outcomes, CGH successfully launched the clinical tests through the Shimadzu-CGH Clinomics Centre clinical service. To date, CGH has conducted over 6,500 tests on patients with hypertension. These experiences have taught me the value of precision and empathy in research, shaping my commitment to maintaining rigorous standards.

Subsequently, I transitioned into roles that required strategic oversight. Being involved in a multi-center clinical trial for COVID-19, using integrated emerging digital tools, such as a cloud-based dashboard, enhances data visibility and enables real-time insights on the enrollment rate. These integrations allowed for faster decision-making and protocol adjustments to mitigate risks, while enabling data-driven resource allocation. Helming such roles reinforced my belief that leadership in research is rooted in integrity, transparency and a relentless focus on patient safety. I also learnt that fostering a culture of continuous learning and adaptability is essential in a rapidly evolving landscape.

Integrating real-world data (RWD) and digital technologies has revolutionized how healthcare researchers, data scientists, and clinical research coordinators interpret and apply research findings. We leverage electronic health records, wearable devices and mobile health applications to gather comprehensive, real-time insights on patient outcomes beyond traditional clinical settings. This approach accelerates the translational process by providing a more nuanced understanding of how interventions perform in diverse, everyday environments.

Digital tools such as artificial intelligence and machine learning algorithms are instrumental in analyzing vast datasets efficiently. They help identify patterns, predict outcomes and inform trial design, making studies more targeted and resource-efficient. For instance, adaptive trial designs enabled by digital platforms, such as response-adaptive randomization, allow us to modify protocols in real time, which can help expedite decision-making and enhance patient outcomes.

“Implementing advanced data validation techniques, real-time oversight, and centralized monitoring systems allows us to identify discrepancies or deviations promptly, ensuring data quality and compliance.”

Importantly, these technologies also enhance patient engagement and retention, as participants can contribute their data, fostering inclusivity and diversity in trials. By integrating RWD with traditional research, we are bridging the gap between clinical efficacy and real-world effectiveness, ultimately leading to more personalized and timely clinical interventions.

Leading with empathy and transparency

My leadership philosophy is encapsulated in the belief that a true leader takes a step back when success is achieved, and stands in front when there are let-downs. This approach fosters a culture of accountability and empowerment within the team.

Prioritizing and recognizing team efforts, when successful milestones are achieved, empowers staff to take ownership of their contributions. This approach cultivates a sense of shared achievement and motivates sustained excellence. Conversely, during challenging phases, such as unexpected trial setbacks or regulatory hurdles, I believe it is crucial to be present and transparent, providing guidance and reassurance. Leading with empathy and transparency ensures that teams remain motivated and committed, even amidst the inherent uncertainties of clinical research. This creates a culture where accountability is balanced with support. It also reminds team members that successes are collective victories and setbacks are collective opportunities for learning, as we build resilience and drive innovation.

Prioritizing patient safety in research and innovation

Maintaining trial integrity and safeguarding patient safety are paramount in fast-moving, complex clinical environments. The biggest differentiators are robust governance frameworks, rigorous monitoring and a culture of transparency. Implementing advanced data validation techniques, real-time oversight, and centralized monitoring systems allows us to identify discrepancies or deviations promptly, ensuring data quality and compliance.

Moreover, open communication among investigators, sponsors, regulatory bodies and patients facilitates early detection of potential issues and swift corrective actions. Training and continual education are vital to maintaining high standards across diverse sites and teams.

Technological innovations, such as blockchain for data traceability and electronic consent systems, further enhance transparency and accountability. Maintaining a patient-centric approach—prioritizing safety, informed consent and ethical considerations—remains the foundation of our work in high-pressure settings. Rigor, vigilance and adaptability are essential to upholding the integrity of trials amid complexity and rapid change.

I believe that hospital leaders contemplating integrating emerging technologies into clinical research should focus on balancing innovation with responsibility.

Firstly, always remember the patient. Technologies should enhance patient safety, improve trial access and generate reliable data that uphold regulatory standards. Transparency with stakeholders, including regulators and patients, builds trust and facilitates sustainable innovation.

Secondly, establish a clear governance framework that delineates standards for data integrity, regulatory compliance and operational efficiency. Engaging multidisciplinary teams— including legal, IT, clinical, and compliance experts—ensures comprehensive oversight.

Thirdly, prioritize staff training to build technological literacy and foster a culture of quality and safety. Embrace pilot projects and phased rollouts to assess feasibility, identify challenges and refine processes before full-scale implementation.

Lastly, leverage partnerships with technology vendors and research organizations to stay abreast of best practices and emerging standards. Regular audits, monitoring and feedback loops are critical to maintaining high standards.

In navigating the evolving landscape of clinical research, leadership grounded in integrity, adaptability and a commitment to patient safety is essential. By harnessing real-world data and digital tools, fostering resilient teams and upholding the highest standards of trial conduct, we can accelerate the translation of research into meaningful health outcomes. At CGH, our collective vision is to innovate healthcare for tomorrow as the trusted care partner, and we endeavour to do so responsibly, lead with empathy and uphold the trust placed in us by patients and society.